Global Pharmaceutical Softgel Capsules Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Pharmaceutical Softgel Capsules Market  Segmentation, By Type (Gelatin Softgel Capsules, Vegetarian Softgel Capsules), Application (Antacid & Antiflatulent Preparations, Ophthalmic Softgel Capsules, Anti-inflammatory Drugs, Antibiotic & Antibacterial Drugs, Cardiovascular Therapy Drugs, Health Supplements, and Others), End-Users (Clinics, Hospitals, Home Care), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) - Industry Trends and Forecast to 2032

Get Exclusive Sample Copy of this Report Here

Pharmaceutical Softgel Capsules Market Size

• The global Pharmaceutical Softgel Capsules Market Size was valued at USD 8.84 Billion in 2024 and is expected to reach USD 13.83 Billion by 2032, at a CAGR of 5.75% during the forecast period
• The market growth is largely fueled by the growing adoption and technological progress within pharmaceutical formulation and drug delivery systems, leading to increased utilization of softgel capsules in both prescription and over-the-counter products.
• Furthermore, rising consumer demand for easy-to-swallow, effective, and high-bioavailability dosage forms is establishing pharmaceutical softgel capsules as the preferred choice for a wide range of therapeutic and supplement applications. These converging factors are accelerating the uptake of softgel capsule solutions, thereby significantly boosting the industry’s growth.

Pharmaceutical Softgel Capsules Market Analysis

• Pharmaceutical softgel capsules, offering a convenient and efficient oral dosage form, are increasingly vital components of modern drug delivery systems in both prescription and non-prescription formulations due to their enhanced bioavailability, ease of swallowing, and ability to encapsulate both hydrophilic and lipophilic substances.
• The escalating demand for softgel capsules is primarily fueled by the growing preference for self-administration, rising geriatric population, and an increasing consumer inclination toward health supplements and advanced drug delivery formats.
• North America dominates the pharmaceutical softgel capsules market with the largest revenue share of 40.01% in 2025, characterized by well-established pharmaceutical infrastructure, high healthcare spending, and a strong presence of key industry players, with the U.S. experiencing substantial growth in softgel-based drug and supplement consumption, particularly across the aging population and wellness-focused consumers, driven by innovations in encapsulation technologies and targeted formulations.
• Asia-Pacific is expected to be the fastest growing region in the pharmaceutical softgel capsules market during the forecast period due to increasing healthcare access, expanding pharmaceutical manufacturing capacity, and rising awareness about nutritional supplementation.
• Gelatin softgel capsules segment is expected to dominate the pharmaceutical softgel capsules market with a market share of 43.2% in 2025, driven by its widespread acceptance, cost-effectiveness, and suitability for a broad range of pharmaceutical and nutraceutical applications.

Report Scope and Pharmaceutical Softgel Capsules Market  Segmentation  

Pharmaceutical Softgel Capsules Market  Trends

“Enhanced Convenience Through Advanced Encapsulation and Delivery Technologies”

• A significant and accelerating trend in the global pharmaceutical softgel capsules market is the deepening integration of advanced encapsulation techniques and innovative drug delivery technologies. This fusion of formulation science and technology is significantly enhancing the convenience, efficacy, and patient compliance associated with softgel capsule administration.

  • For instance, technologies like Licaps by Capsugel enable the encapsulation of liquids and semi-solids without the need for heat, preserving the stability of heat-sensitive compounds. Similarly, enteric-coated softgel innovations offer targeted drug release, bypassing the stomach and releasing active ingredients in the intestine, enhancing therapeutic efficacy.

• Advanced encapsulation allows for the inclusion of complex drug combinations, controlled release profiles, and improved bioavailability. For example, lipid-based delivery systems incorporated in softgels help increase the absorption of poorly water-soluble drugs, leading to more effective outcomes. Furthermore, innovations in capsule shell materials are improving stability, reducing oxidation, and extending shelf life.
• The seamless integration of these technologies into pharmaceutical and nutraceutical formulations facilitates enhanced patient experience, particularly for populations with swallowing difficulties or requiring precise dosing. Through a single dosage form, softgels can deliver combination therapies, improve absorption, and reduce gastrointestinal irritation, creating a more effective and user-friendly treatment experience.
• This trend towards more intelligent, effective, and user-centric softgel solutions is fundamentally reshaping expectations for oral drug delivery. Consequently, companies such as Catalent and Sirio Pharma are developing specialized softgel products with advanced delivery mechanisms, including sustained and targeted release features.
• The demand for pharmaceutical softgel capsules that offer enhanced convenience, stability, and bioavailability is growing rapidly across both therapeutic and supplement markets, as healthcare providers and consumers increasingly prioritize treatment efficacy and patient compliance.

Pharmaceutical Softgel Capsules Market Dynamics

Driver

“Growing Need Due to Increased Demand for Patient-Centric and Efficient Drug Delivery Systems”

• The increasing prevalence of chronic diseases, aging populations, and the rising need for patient-friendly dosage forms are significant drivers for the heightened demand for pharmaceutical softgel capsules.

  • For instance, in April 2024, Catalent, Inc. announced the expansion of its softgel capsule manufacturing capabilities to meet the growing global demand for advanced oral drug delivery systems, with a focus on bioavailability-enhancing technologies. Such strategic initiatives by key players are expected to drive the pharmaceutical softgel capsules market growth during the forecast period.

• As patients and healthcare providers increasingly seek convenient, easy-to-swallow, and fast-acting medication options, softgel capsules offer advantages such as improved absorption, reduced gastrointestinal irritation, and compatibility with a wide range of active ingredients, making them a compelling alternative to traditional tablets or hard capsules.
• Furthermore, the growing popularity of nutraceuticals, personalized medicine, and combination therapies is making softgel capsules an integral part of modern pharmaceutical and health supplement product lines, offering flexible formulation and rapid consumer acceptance.
• The convenience of single-dose formats, enhanced stability for sensitive compounds, and reduced pill burden are key factors propelling the adoption of softgel capsules in both therapeutic and preventive healthcare markets. The trend toward consumer self-care, along with increasing availability of innovative and user-friendly softgel formulations, further contributes to market growth.

Restraint/Challenge

“Concerns Regarding Stability, Regulatory Compliance, and Production Costs”

• Concerns surrounding the stability of active pharmaceutical ingredients (APIs) within softgel capsules, along with stringent regulatory requirements, pose a significant challenge to broader market penetration. As softgel capsules involve complex formulations and encapsulation processes, they are susceptible to issues such as ingredient interactions, degradation, and capsule leakage, raising anxieties among manufacturers regarding product consistency and shelf life.

  • For instance, reports of formulation instability or dissolution failures in softgel-based products have made some companies cautious about fully adopting this delivery format, especially for heat- or moisture-sensitive drugs.

• Addressing these challenges through improved shell technologies, advanced encapsulation techniques, and compliance with global Good Manufacturing Practices (GMP) is crucial for building regulatory and market confidence. Companies such as Catalent and Aenova emphasize their expertise in formulation stability and regulatory compliance in their product development and client communications. Additionally, the relatively high production cost of softgel capsules compared to conventional tablets or hard capsules can be a barrier to adoption for cost-sensitive pharmaceutical companies, particularly in developing regions or for generic drug manufacturers. While advancements in manufacturing efficiency are helping reduce costs, specialized materials and equipment often result in a higher price tag.
• While prices are gradually decreasing due to innovations and economies of scale, the perceived premium for softgel technology can still hinder widespread adoption, especially for therapies where traditional dosage forms are considered adequate.
• Overcoming these challenges through robust R&D, investment in scalable production methods, and educational outreach about the clinical benefits of softgel formats will be vital for sustained market growth.

Pharmaceutical Softgel Capsules Market Scope

The market is segmented on the basis of type, application, end-users, and distribution channel.

• By Type

On the basis of type, the pharmaceutical softgel capsules market is segmented into gelatin softgel capsules and vegetarian softgel capsules. The gelatin softgel capsules segment dominates the largest market revenue share of 43.2% in 2025, driven by its widespread usage, cost-effectiveness, and suitability for encapsulating a broad range of pharmaceutical and nutraceutical compounds. Pharmaceutical manufacturers often prioritize gelatin softgels for their proven track record in ensuring drug stability, ease of manufacturing, and patient acceptability. The market also sees strong demand for gelatin-based formulations due to their compatibility with various drug types and established supply chains for gelatin sourcing.

The vegetarian softgel capsules segment is anticipated to witness the fastest growth rate of 21.7% from 2025 to 2032, fueled by increasing adoption among vegan and vegetarian populations as well as rising demand in regions with dietary or religious restrictions on animal-derived products. Vegetarian capsules offer similar functionality to gelatin types while providing a plant-based alternative, making them suitable for a wider consumer base. Their growing acceptance in both pharmaceutical and nutraceutical applications is also supported by advancements in plant-derived polymers that enhance capsule integrity and performance.

• By Application

On the basis of application, the pharmaceutical softgel capsules market is segmented into antacid & antiflatulent preparations, ophthalmic softgel capsules, anti-inflammatory drugs, antibiotic & antibacterial drugs, cardiovascular therapy drugs, health supplements, and others. The health supplements segment held the largest market revenue share in 2025, driven by the growing consumer preference for wellness products and nutritional supplements delivered through convenient and effective softgel formats. Health supplements benefit from enhanced bioavailability and patient compliance, fueling their dominance in the market.

The anti-inflammatory drugs segment is expected to witness the fastest CAGR from 2025 to 2032, owing to the rising prevalence of chronic inflammatory conditions and increasing demand for targeted, controlled-release drug delivery systems. Softgel capsules provide an effective means of delivering anti-inflammatory agents with improved absorption and reduced gastrointestinal side effects, contributing to their rapid adoption in this therapeutic category..

• By End User

On the basis of end-users, the pharmaceutical softgel capsules market is segmented into clinics, hospitals, and home care. The hospitals segment held the largest market revenue share in 2025, driven by the high demand for advanced drug delivery systems in inpatient and outpatient treatments. Hospitals benefit from the precise dosing, improved bioavailability, and ease of administration that softgel capsules offer, making them a preferred choice for a wide range of therapeutic areas.

The home care segment is expected to witness the fastest CAGR from 2025 to 2032, fueled by the growing trend of self-medication and increasing consumer preference for convenient, ready-to-use dosage forms. The rise in chronic diseases and aging populations has also contributed to the demand for softgel capsules that can be easily administered at home, enhancing patient compliance and quality of life.

• By Distribution Channel

On the basis of distribution channel, the pharmaceutical softgel capsules market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others. The hospital pharmacy segment held the largest market revenue share in 2025, driven by the significant procurement of softgel capsules for inpatient care and the preference of healthcare institutions for quality-assured drug delivery systems.

The online pharmacy segment is expected to witness the fastest CAGR from 2025 to 2032, fueled by the rapid growth of e-commerce, increasing consumer convenience, and expanding digital healthcare platforms. Online pharmacies provide easy access to a wide range of pharmaceutical softgel capsule products, enabling direct-to-consumer sales and contributing to the market’s expansion across diverse geographic regions.

Pharmaceutical Softgel Capsules Market Regional Analysis

• North America dominates the pharmaceutical softgel capsules market with the largest revenue share of 40.01% in 2024, driven by the high demand for advanced drug delivery systems and increasing healthcare expenditure.
• Consumers and healthcare providers in the region highly value the enhanced bioavailability, convenience, and patient compliance offered by softgel capsules across various therapeutic and supplement applications.
• This widespread adoption is further supported by strong pharmaceutical manufacturing infrastructure, a technologically advanced healthcare system, and growing preference for innovative dosage forms, establishing softgel capsules as a favored choice in both hospital and retail pharmacy settings.

U.S. Pharmaceutical Softgel Capsules Market Insight

The U.S. pharmaceutical softgel capsules market captured the largest revenue share of 81% within North America in 2025, fueled by the rapid adoption of advanced drug delivery systems and growing consumer preference for convenient oral dosage forms. Patients and healthcare providers increasingly prioritize softgel capsules for their enhanced bioavailability and ease of swallowing. The rising demand for nutraceuticals and dietary supplements, combined with strong investments in pharmaceutical innovation and manufacturing, further propels the softgel capsule industry. Moreover, the increasing integration of softgel technology with novel formulations and health supplements is significantly contributing to the market’s expansion.

Europe Pharmaceutical Softgel Capsules Market Insight

The European pharmaceutical softgel capsules market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by stringent regulatory standards and the escalating demand for advanced drug delivery systems. The increase in healthcare infrastructure development, coupled with growing consumer preference for convenient and effective dosage forms, is fostering the adoption of softgel capsules. European patients and healthcare providers are also drawn to the improved bioavailability and patient compliance these products offer. The region is experiencing significant growth across hospital, retail pharmacy, and home care applications, with softgel capsules being incorporated into both prescription medications and over-the-counter health supplements..

U.K. Pharmaceutical Softgel Capsules Market Insight

The U.K. pharmaceutical softgel capsules market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing consumer preference for convenient and effective drug delivery systems. Additionally, rising awareness about health and wellness is encouraging both patients and healthcare providers to choose softgel capsules for improved bioavailability and ease of use. The U.K.’s well-established pharmaceutical industry, alongside its robust healthcare infrastructure and growing e-commerce platforms for pharmaceuticals, is expected to continue to stimulate market growth.

Germany Pharmaceutical Softgel Capsules Market Insight

The German pharmaceutical softgel capsules market is expected to expand at a considerable CAGR during the forecast period, fueled by increasing awareness of advanced drug delivery technologies and the demand for high-quality, sustainable pharmaceutical products. Germany’s well-developed healthcare infrastructure, combined with its emphasis on pharmaceutical innovation and regulatory compliance, promotes the adoption of softgel capsules, particularly in prescription medications and nutraceuticals. The integration of softgel technology with novel formulations is also becoming increasingly prevalent, with a strong preference for effective, safe, and eco-conscious dosage forms aligning with local consumer and industry expectations.

Asia-Pacific Pharmaceutical Softgel Capsules Market Insight

The Asia-Pacific pharmaceutical softgel capsules market is poised to grow at the fastest CAGR of over 24% in 2025, driven by increasing healthcare expenditure, rising disposable incomes, and technological advancements in countries such as China, Japan, and India. The region's growing inclination towards advanced drug delivery systems, supported by government initiatives promoting healthcare infrastructure development and pharmaceutical innovation, is driving the adoption of softgel capsules. Furthermore, as APAC emerges as a manufacturing hub for pharmaceutical ingredients and softgel technologies, the affordability and accessibility of softgel capsules are expanding to a wider patient and consumer base.

Japan Pharmaceutical Softgel Capsules Market Insight

The Japan pharmaceutical softgel capsules market is gaining momentum due to the country’s advanced healthcare infrastructure, rapid urbanization, and increasing demand for convenient drug delivery systems. The Japanese market places significant emphasis on safety and efficacy, and the adoption of softgel capsules is driven by the growing prevalence of chronic diseases and an aging population. The integration of softgel technology with innovative formulations, such as nutraceuticals and prescription drugs, is fueling growth. Moreover, Japan’s aging population is likely to spur demand for easier-to-administer, effective, and safe pharmaceutical dosage forms across both residential and institutional healthcare settings.

China Pharmaceutical Softgel Capsules Market Insight

The China pharmaceutical softgel capsules market accounted for the largest market revenue share in Asia Pacific in 2025, attributed to the country’s expanding middle class, rapid urbanization, and increasing healthcare expenditure. China stands as one of the largest markets for pharmaceutical and nutraceutical products, with softgel capsules becoming increasingly popular due to their enhanced bioavailability and patient compliance. The government’s focus on improving healthcare infrastructure and the presence of strong domestic manufacturers offering affordable softgel products are key factors propelling the market growth in China.

Pharmaceutical Softgel Capsules Market Share

The Pharmaceutical Softgel Capsules  industry is primarily led by well-established companies, including:

• Catalent, Inc. (USA)
• Thermo Fisher Scientific Inc. (USA)
• Capsugel (USA – acquired by Lonza Group Ltd., Switzerland)
• CAPTEK (USA)
• Eurocaps Ltd. (UK)
• Amway (USA)
•  Sirio Pharma Co., Ltd. (China)
•  Strides Pharma Science Limited (India)
•  INTERNATIONAL VITAMIN CORPORATION (USA)
•  Weihai Baihe Biology Technological Co., Ltd. (China)
•  Yuwang (China)
•  Aenova Holding GmbH (Germany)
•  Softgel Healthcare (India)
•  Douglas Laboratories (USA)
•  MEDGEL (India)
•  Softcaps (Titanium Technologies India Pvt Ltd) (India)
•  Medikonda Nutrients (India)
•  Renown Pharmaceuticals Pvt. Ltd. (India)
•  Bolivac Pharmaceutical (India)
•  Arion Healthcare (India)
•  Iscon Life Sciences (India)
•  Fuji Capsule Co., Ltd. (Japan)
•  Lonza Group Ltd. (Switzerland)
•  Nature’s Bounty (USA)
•  Robinson Pharma Inc. (USA)
•  BASF SE (Germany)
•  Procaps Group (Colombia)

Latest Developments in Global Pharmaceutical Softgel Capsules Market

• On September 19, 2024, Lonza Group Ltd. inaugurated the Innovaform Accelerator, a dedicated oral drug product development center in Colmar, France. This facility is designed to support pharmaceutical partners with accelerated formulation and capsule-based drug development projects. The opening of this center marks a pivotal step in Lonza’s strategy to co-develop advanced therapeutic solutions and further solidifies its commitment to collaborative innovation in the global pharmaceutical softgel and hard capsule space.
• On June 20, 2024, Lonza Group Ltd. expanded its Capsugel Enprotect product line with the launch of Capsugel Enprotect Size 9 capsules. Specifically developed for rodent preclinical trials, this smaller format supports early-stage drug formulation and targeted intestinal delivery research. This strategic move emphasizes Lonza’s role in accelerating pharmaceutical innovation and extending its advanced capsule technologies into preclinical development settings, reinforcing its leadership in the global pharmaceutical encapsulation market.
• On November 1, 2022, Lonza Group Ltd. launched Capsugel Enprotect, a next-generation, coating-free enteric capsule designed to deliver acid-sensitive pharmaceutical ingredients directly to the intestine. This innovation reflects the company's ongoing commitment to enabling advanced drug delivery solutions and enhancing therapeutic outcomes. By removing the need for an external enteric coating, this launch streamlines the development process for oral dosage forms and strengthens Lonza’s position in the evolving softgel and hard capsule market.

SKU-59070